Radiotherapy News and Research RSS Feed - Radiotherapy News and Research

Radiation therapy (in North America), or radiotherapy (in the UK and Australia) also called radiation oncology, and sometimes abbreviated to XRT, is the medical use of ionizing radiation as part of cancer treatment to control malignant cells (not to be confused with radiology, the use of radiation in medical imaging and diagnosis).
Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

Clinicians perform UK’s first MRI-guided focused ultrasound treatment for prostate cancer

INSIGHTEC congratulates the medical team at Imperial College Healthcare NHS Trust for performing the first MR-guided focused ultrasound treatment in the United Kingdom for prostate cancer. [More]
Gene therapy shows promise in treating glioblastoma

Gene therapy shows promise in treating glioblastoma

A team from the International School for Advanced Studies in Trieste has obtained very promising results by applying gene therapy to glioblastoma. [More]
Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Single breath-hold for more than five minutes could make targeted radiotherapy feasible

Researchers at the University of Birmingham working with clinical teams at University Hospitals Birmingham NHS Foundation Trust have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath holds of over five minutes, opening the door for targeted radiotherapy to be administered with just one dose in each daily session. [More]
Lawson Health scientists capture prostate cancer images using unique molecule

Lawson Health scientists capture prostate cancer images using unique molecule

Scientists at Lawson Health Research Institute are the first in Canada to capture prostate cancer images using a new molecule. Known as a Prostate Specific Membrane Antigen (PSMA) probe, the new molecule is used in Positron Emissions Tomography (PET) scans. [More]
Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

Ga-68 DOTATATE PET/CT scans more effective than current imaging standard for detecting NETS

A recent study reported in the May issue of the Journal of Nuclear Medicine demonstrates that Ga-68 DOTATATE PET/CT scans are superior to In-111 pentetreotide scans, the current imaging standard in the United States for detecting neuroendocrine tumors, and could significantly impact treatment management. [More]
Combination of hormone therapy and radiotherapy halves risk of death from prostate cancer

Combination of hormone therapy and radiotherapy halves risk of death from prostate cancer

A longitudinal Nordic study, comparing the results of hormone (antiandrogen) therapy with or without the addition of local radiotherapy, shows that a combination of treatments halves the risk of death from prostate cancer 15 years after diagnosis. This according to a follow-up study recently published in the journal European Urology. [More]
Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

Patient-oriented online health resources can impact clinical outcomes of pancreatic cancer patients

The Internet has become a powerful and important resource for daily life. When patients receive a medical diagnosis, particularly a difficult one like pancreatic cancer, the web can be an essential information tool, helping to enable patients to have meaningful discussions with health care providers. However, new research from Beth Israel Deaconess Medical Center published today in JAMA Surgery suggests that online information about pancreatic cancer is often written at a prohibitively high reading level and lacks accuracy concerning alternative therapies. [More]
Stereotactic body radiation therapy for NSCLC patients may raise non-cancer mortality risk

Stereotactic body radiation therapy for NSCLC patients may raise non-cancer mortality risk

Researchers have found that treating patients who have early stage non-small cell lung cancer (NSCLC) with a type of radiotherapy called stereotactic body radiation therapy (SBRT) is associated with a small but increased risk of death from causes other than cancer. [More]
Radiation therapy better than chemotherapy for stage IIa testicular cancer patients

Radiation therapy better than chemotherapy for stage IIa testicular cancer patients

A large study of testicular cancer patients has shown that radiation therapy is a better treatment than chemotherapy for patients with stage IIa disease (where one or more regional lymph nodes contain cancer cells but they are less than 2cms in diameter). [More]
New form of SBRT to deliver radiation to specific area of prostate cancer

New form of SBRT to deliver radiation to specific area of prostate cancer

University Hospitals Seidman Cancer Center physicians have started the world's first clinical trial using a new form of stereotactic body radiotherapy (SBRT) to deliver radiation to a specific area of the prostate invaded with cancer - instead of the entire gland. The study aims to determine if treating a targeted cancer region within the prostate in early stage prostate cancer can increase treatment options and reduce the side effects of radiation. [More]
Single dose of intraoperative radiotherapy effective for early stage breast cancer patients

Single dose of intraoperative radiotherapy effective for early stage breast cancer patients

In the South East of England, a patient experience study of 18 early stage breast cancer patients who opted for single dose intraoperative radiotherapy, found positive patient reported outcomes for this alternative to standard daily external beam radiotherapy. [More]
Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

Nivolumab drug shows survival benefit in phase III trial of patients with head and neck cancer

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy. [More]
SBRT for prostate cancer treatment offers higher cure rate than many traditional approaches

SBRT for prostate cancer treatment offers higher cure rate than many traditional approaches

A five-year study shows that Stereotactic Body Radiation Therapy (SBRT) to treat prostate cancer offers a higher cure rate than more traditional approaches, according to researchers at UT Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center. [More]
Radiotherapy needs likely to increase in all European countries by 2025

Radiotherapy needs likely to increase in all European countries by 2025

The demand for radiotherapy across all European countries will increase by an average of 16% between 2012 and 2025, with the highest expected increase being for prostate cancer cases (24%), according to a new study published in Radiotherapy and Oncology. [More]
International scientists discuss new treatments for non small cell lung cancer

International scientists discuss new treatments for non small cell lung cancer

More than 30 prominent international scientists gathered to discuss the state-of-the-art, as well as promising future approaches for the treatment of lung cancer at the stunning 17th century Borgo San Luigi, in Monteriggion, in the heart of the Tuscany countryside. [More]
Moffitt study reports that liver metastases have different sensitivities to radiation therapy

Moffitt study reports that liver metastases have different sensitivities to radiation therapy

Radiation is a commonly used therapeutic option to treat liver metastases, with the majority of tumors maintained under control after one year. However, some patients do not respond as well to radiation treatment, and the factors that predict patient outcomes are unclear. Moffitt Cancer Center researchers report that liver metastases have different sensitivities to radiation therapy based on the location of the primary tumor. [More]
RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma initiates phase II study of BEKINDA for irritable bowel syndrome

RedHill Biopharma Ltd. (NASDAQ; RDHL) (TASE: RDHL) (“RedHill” or the “Company”), a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced that it has initiated a randomized, double-blind, 2-arm parallel group Phase II clinical study in the U.S. evaluating the safety and efficacy of BEKINDA™ 12 mg in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). [More]
Shortened RT schedule has similar efficacy as conventional RT schedule in low-risk prostate cancer patients

Shortened RT schedule has similar efficacy as conventional RT schedule in low-risk prostate cancer patients

Of the more than 220,000 patients newly diagnosed with prostate cancer in 2015, the vast majority will have had early-stage disease at low risk for recurrence. [More]
MedUni Vienna researchers identify reason for chemoresistance in small cell lung cancer

MedUni Vienna researchers identify reason for chemoresistance in small cell lung cancer

Small cell lung cancer is not usually detected until it is at an advanced stage, when metastases have already formed. Chemotherapy is very effective initially but, within a year, cancer recurs and this time does not respond to a course of chemotherapy. The research group headed by Gerhard Hamilton, University Department of Surgery at MedUni Vienna, has now managed to identify the reason for this chemoresistance. [More]
Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Both female and male chemotherapy-treated survivors of childhood cancer have an increased risk of impaired fertility, but results suggest that the risk in women is limited to those given specific chemotherapy drugs. [More]
Advertisement
Advertisement